What is Ginkgo Bioworks's D&A?

Ginkgo Bioworks (DNA) reported D&A of $12.8M in Q1 2026.

How has Ginkgo Bioworks's D&A changed year-over-year?

Ginkgo Bioworks's D&A decreased by 13.6% year-over-year, from $14.82M to $12.8M.

What is the long-term trend for Ginkgo Bioworks's D&A?

Over 4 years (2021 to 2025), Ginkgo Bioworks's D&A has grown at a 19.3% compound annual growth rate (CAGR), from $29.08M to $58.99M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ginkgo Bioworks DNA D&A

D&A at other companies

Charles River LaboratoriesCRL

$67.15M-44.2%

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Emergent BiosolutionsEBS

$16.5M+1.2%

RevvityRVTY

——

Segments

By segment

See full

Reportable Segment$12.8M-13.6%

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's D&A?: Ginkgo Bioworks (DNA) reported D&A of $12.8M in Q1 2026.
How has Ginkgo Bioworks's D&A changed year-over-year?: Ginkgo Bioworks's D&A decreased by 13.6% year-over-year, from $14.82M to $12.8M.
What is the long-term trend for Ginkgo Bioworks's D&A?: Over 4 years (2021 to 2025), Ginkgo Bioworks's D&A has grown at a 19.3% compound annual growth rate (CAGR), from $29.08M to $58.99M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.